Abstract: The present invention generally relates to a process for manufacturing gel composition of Luliconazole for treatment of vaginal fungal infections cooling 50% quantity of purified water at 4° C.; adding 0.10-0.30% of Carbopol 934, 5-15% of poloxamer 188 and 15-25% of poloxamer 407 slowly under constant stirring and placing at 4° C., until a clear solution is obtained; adding 0.1-0.5% HPMC K100M gradually under stirring and leaving for 24 hours at room temperature; adding 0.5-2% Luliconazole solution slowly under high speed homogenizer; adding 0-0.5% Sodium methyl parabens and 0-1% Sodium propyl parabens solution under constant stirring; adding 0.1-0.5% sodium chloride under stirring; checking and maintaining pH of the obtained solution; and preparing the obtained solution volume to 100% with purified water and stirring for 30 min for manufacturing gel composition of Luliconazole.

Abstract: The present invention generally relates to a process for preparing polymeric-based nanoparticle of RPD coated with Tf and RVG comprises dissolving 1-12 wt % of RPD and 8-96 wt % of lipid in isopropyl alcohol (IPA) and heating the solution to 70° C. to create the organic phase; adding prepared organic solution to the 0-2 wt % of aqueous surfactant solution using a syringe at 70° C. temperature; swirling the obtained solution at 1000 rpm on a high speed homogenizer for 15 minutes after the solvent is evaporated using a magnetic stirrer to create the SLNs dispersion; and adding 45-100 wt % of Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 45-100 wt % of N-Hydroxysulfosuccinimide (NHS), which included activating the carboxylic acid terminal groups and conjugating Tf and RVG to RPD's PLGA nanoparticles.

Abstract: The system comprises a collection unit for procuring doxorubicin, diethyl ether, alkaline water and a plurality of subject animals; a pre-processor unit for acclimatizing collected plurality of subject animals for 7 days standard laboratory condition; a classification processor unit for dividing subject animals into four groups; a treating unit for feeding subject animals with standard semi purified diet along with normal drinking water and standard semi purified diet along with Zam water p.o at libitum, or injecting with Dox i.p. on first day of protocol fed with standard semi purified diet along with normal drinking water or Dox i.p. on first day of protocol thereby treating with Zam water p.o at libitum for 28 days; a monitoring processor unit for monitoring physiological and behavioral changes of plurality of subject animals; and an analysis processor unit for estimating a set of biochemical parameters and stool sample of the plurality of subject animals.

Abstract: Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

Abstract: Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.

Abstract: Self-nanoemulsifying drug delivery system (SNEDDS) composition are provided. The compositions include at least one chemotherapeutic compound or a pharmaceutically acceptable salt thereof or mixture thereof, at least one biocompatible surfactant, wherein the at least one biocompatible surfactant includes surfactin, and at least one co-surfactant. Methods of enhancing the bioavailability of the chemotherapeutic compound and for treating cancer are also provided.

Abstract: A method (100) for detecting mycotoxins in organic material, wherein the method (100) comprises of: storing about 2-5 grams of organic material in a temperature less than room temperature; adding a solvent Acetonitrile in the stored organic material to form a first mixture, wherein the first mixture is transferred to a 40-60 ml tubes, centrifuged and shaken for a defined interval; adding 0.5-3 ml of supernatant, 80-120 mg of cyclo-18-carbon (C18) and 200-400 mg of Magnesium sulfate to the first mixture to form a second mixture; and filtering the formed second mixture using a filter syringe to obtain a filtrate, wherein the mycotoxins are detected from the obtained filtrate using Ultra High-Performance Liquid Chromatography (UHPLC) coupled with a mass spectrometer.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.

Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.